{"id":"W2749627335","doi":"10.1016/j.cgh.2017.08.025","title":"Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set","year":2017,"lang":"en","type":"review","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":67,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University; Robarts Clinical Trials; University of Alberta; University of Calgary","funders":"UCB Pharma; Genentech; Eisai; Optimer Pharmaceuticals; Janssen Pharmaceuticals; Gilead Sciences; Roche; Johnson and Johnson; Teva Pharmaceutical Industries; EMD Serono; Ferring Pharmaceuticals; Novartis; Tillotts Pharma; Schering-Plough; Boehringer Ingelheim; Amgen; Pfizer; Shire; Merck; Orexigen Therapeutics; Bristol-Myers Squibb; Takeda Pharmaceutical Company; AbbVie; GlaxoSmithKline","keywords":"Medicine; Ulcerative colitis; Outcome (game theory); Core (optical fiber); Clinical trial; Set (abstract data type); Intensive care medicine; MEDLINE; Internal medicine; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.07734118,0.002486132,0.02485896,0.008678636,0.0007757081,0.006271296,0.004931803,0.003097605,0.003413861],"category_scores_gemma":[0.1801841,0.001502171,0.02274864,0.007992156,0.002084389,0.00454546,0.004659102,0.004382233,0.0002919178],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005005275,"about_ca_system_score_gemma":0.009577316,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003195685,"about_ca_topic_score_gemma":0.00874364,"domain_scores_codex":[0.9168162,0.03399986,0.03507957,0.00557673,0.007752002,0.0007756032],"domain_scores_gemma":[0.802035,0.1676853,0.02110389,0.003313421,0.005125622,0.0007366427],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.001368163,0.0000270639,0.002240766,0.7789854,0.1231269,0.00006320947,0.0002877619,0.0005525466,0.0002344048,0.002212399,0.002327698,0.08857365],"study_design_scores_gemma":[0.002806221,0.0003834918,0.006555274,0.4232357,0.5340706,0.0003255233,0.000348657,0.000746629,0.0003894932,0.006780753,0.02416366,0.0001940046],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005667601,0.9971071,0.001020225,0.0003770574,0.0001755366,0.0002595465,0.0003237689,0.00001333086,0.0001566664],"genre_scores_gemma":[0.0527316,0.9289648,0.01089325,0.003204923,0.0004340494,0.002209367,0.001341137,0.00005428771,0.0001665206],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9226588,"threshold_uncertainty_score":0.4090241,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.627853148234873,"score_gpt":0.5701538333153546,"score_spread":0.05769931491951841,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}